

University of Groningen

## Homomultimeric structure by assembly of sirv2 p98 proteins or p98 variants, conjugate and uses thereof

Quax, Tessa E.F.; Soizick, Lucas; Forterre, Patrick; Prangishvili, David

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*  
2012

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Quax, T. E. F., Soizick, L., Forterre, P., & Prangishvili, D. (2012). Homomultimeric structure by assembly of sirv2 p98 proteins or p98 variants, conjugate and uses thereof. (Patent No. *WO2012098243*).

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*



- (51) International Patent Classification:  
C07K 14/01 (2006.01) B82Y 5/00 (2011.01)
- (21) International Application Number:  
PCT/EP2012/050902
- (22) International Filing Date:  
20 January 2012 (20.01.2012)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
11305058.7 20 January 2011 (20.01.2011) EP
- (71) Applicants (for all designated States except US): **INSTITUT PASTEUR** [FR/FR]; 25-28 Rue du Docteur Roux, F-75724 Paris Cedex 15 (FR). **UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)** [FR/FR]; 4 Place Jussieu, F-75005 Paris (FR). **UNIVERSITE PARIS-SUD 11** [FR/FR]; 15 Rue Georges Clémenceau, F-91405 Orsay Cedex (FR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **QUAX, Tessa E.F.** [NL/FR]; 13, boulevard du Lycée, 92170 Vanves (FR). **LUCAS, Soizick** [FR/FR]; 22, avenue Marcelin Berthelot, F-92320 Chatillon (FR). **FORTERRE, Patrick** [FR/FR]; 2, rue du Colonel Candelot, F-92340 Bourg La Reine (FR). **PRANGISHVILI, David** [DE/FR]; 62, rue des Chantiers, F-78000 Versailles (FR).
- (74) Agent: **Ernest GUTMANN - Yves PLASSERAUD SAS - ALMOND-MARTIN Carol, BARBE Laurent, DESAIX Anne, PARIS Fabienne, VAILLANT Jeanne, RAMEY**

**Daniel, SELLIN Carole, VILLEGER Ludovic, ROBERT Mathias, RACINE Sophie**; 3, rue Auber, F-75009 Paris (FR).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HOMOMULTIMERIC STRUCTURE BY ASSEMBLY OF SIRV2 P98 PROTEINS OR P98 VARIANTS, CONJUGATE AND USES THEREOF




Fig. 5

(57) Abstract: The present invention relates to a homomultimeric protein structure constituted by assembled monomers of the P98 protein of *Sulfolobus islandicus* rod-shaped virus 2 (SIRV2) or assembled monomer variants of said P98 protein. In a particular embodiment, this homomultimeric protein structure has a seven-fold rotational symmetry, and is found in an open conformation or closed conformation. A particular structure has the form of baseless 7-face pyramid. The invention also relates to a conjugate comprising or consisting of a homomultimeric protein structure of the invention to which one or more heterologous molecule(s) is attached. Furthermore, the invention also concerns a homomultimeric protein structure or a conjugate of the invention, inserted into or exposed at the surface of a lipid layer or bilayer, of a vesicle or of a cell, and their uses thereof.

## HOMOMULTIMERIC STRUCTURE BY ASSEMBLY OF SIRV2 P98 PROTEINS OR P98 VARIANTS, CONJUGATE AND USES THEREOF

### FIELD OF THE INVENTION

5           The present invention relates to a homomultimeric protein structure constituted by assembled monomers of the P98 protein of *Sulfolobus islandicus* rod-shaped virus 2 (SIRV2) or assembled monomer variants of said P98 protein or assembled chimeric polypeptides comprising or consisting of the C-terminal part of said SIRV2 P98 protein fused to a transmembrane domain. In a particular embodiment, this  
10 homomultimeric protein structure has a seven-fold rotational symmetry, and is found in an open conformation or closed conformation. A particular structure has the form of baseless 7-face pyramid. The invention also relates to a conjugate comprising or consisting of a homomultimeric protein structure of the invention to which one or more heterologous molecule(s) is attached. Furthermore, the invention also concerns  
15 a homomultimeric protein structure or a conjugate of the invention, inserted into or exposed at the surface of a lipid layer, of a vesicle or of a cell, and their uses thereof.

### BACKGROUND OF THE INVENTION

20           The vast majority of known archaeal viruses carries double-stranded (ds) DNA genomes and differ morphologically from dsDNA viruses of the two other domains of life, Bacteria and Eukarya (1). Moreover, the genomes of these viruses are also unique. The functions of more than 90% of putative genes cannot be identified due to the lack of homologues in the extant databases (1). Limited knowledge of the biology of archaeal viruses is one reason for our poor understanding of viral gene functions.  
25 Archaeal viral cycles have unusual features, which was recently demonstrated by the discovery of a unique virion release mechanism exploited by the *Sulfolobus islandicus* rod-shaped virus 2 (SIRV2) (2) and the *Sulfolobus* turreted icosahedral virus (STIV) (3). Among archaeal viruses, SIRV2 and STIV are the best studied with respect to host cell interactions. It was demonstrated that both are lytic viruses and  
30 that SIRV2 causes massive degradation of the host chromosome. Virion assembly takes place in the cytoplasm and coincides with the appearance of numerous prominent virus-associated pyramids (VAPs) on the host cell surface, which point

outwards and rupture the S-layer. Shortly after their formation, VAPs open to the outside and create large apertures through which the virions escape from the cell (2, 3). The discovery of this unique virion release system raised questions regarding the nature of the VAP and mechanism of its formation.

5       The present application reports the isolation and purification of the VAPs formed by SIRV2 in *S. islandicus*. The inventors have shown that this structure is constituted by multiple copies of a sole protein, and that the assembly of this protein forms a very stable structure when submitted to extreme temperature and pH conditions. Moreover, the inventors have shown that this structure may, in an embodiment, be  
10 obtained, in various cell types, only by expressing the nucleic acid encoding the protein. Finally, the structure inserts into lipid layers or bilayers, with a part exposed out of the layer or bilayer. Therefore, the structure disclosed in the present application constitutes an excellent tool to study interaction and membrane dynamics, as well as to expose heterologous molecule(s) at the surface of lipidic  
15 structures or at the surface of cells.

## BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1:** Negative contrast electron micrographs of isolated VAPs. (A) Top view and (B) side view of intact VAPs. (C) A single triangular face detached from a  
20 VAP. (D) Top view of a VAP in the open conformation. (E) Partially broken VAP in the open conformation (scale bars, 100 nm.) (F) Top view of a VAP in the open conformation.

**Figure 2:** Cryo-electron micrographs of isolated VAPs. (A) Single curved face of a VAP. (B) Two VAPs from the top (scale bars, 100 nm.)

25       **Figure 3:** Isolation and constituents of VAPs. (A) SDS-PAGE of fractions obtained during immunoprecipitation and purification of VAPs. "M", crude membrane extract; "V", immunoprecipitated fraction; "W1-W4", four successive washes of the immunoprecipitate. Proteins were stained with SYPRO Ruby. (B) The same as in A but stained for phospholipids using Sudan Black. The P98 band in lane "V" is  
30 indicated with an asterisk (\*). The positions of proteins with known molecular masses (in kDa) are indicated with bars.

**Figure 4:** Negative contrast electron micrographs and P98 immunolabelling of VAPs. (A, B, and C) Purified VAPs seen from different angles. (D and E) Thawed cryosections through SIRV2-infected cells. The arrows in C indicate three individual VAPs, visualised from the side (empty arrows) and from below (filled arrows). (scale bars in A-C, 100 nm; scale bars in D and E, 200 nm).

**Figure 5:** VAP structure. (A) Negative contrast electron micrograph and P98 immunolabelling of a partially disrupted VAPs. (B) Schematic representation of the image in A. (C) Schematic 3D reconstruction of the native VAP structure based on the images in A and B. The lengths and angles were measured from the image in A. (scale bar, 100 nm).

**Figure 6:** Heterologous expression of SIRV2-ORF98 in *S. acidocaldarius*. (A, B) SDS-PAGE of membrane fractions from the following samples: (1-3), uninfected *S. islandicus*; (4-6) SIRV2-infected *S. islandicus*, 10 h p.i.; (7-9) *S. acidocaldarius* 1059 expressing SIRV2-ORF98. The samples were loaded without diluted and with dilutions of 1:10 and 1:100. The positions of proteins with known molecular masses (in kDa) are indicated with bars. The asterisk (\*) shows the band containing P98. (A) Coomassie Blue-stained gel. (B) Western hybridisation of a duplicate of the gel in A with antibodies against SIRV2-P98. (C) Thin section through *S. acidocaldarius* 1059 expressing SIRV2-P98. The arrow indicates a VAP (scale bar, 200 nm).

**Figure 7:** Heterologous expression of SIRV2-ORF98 in *E. coli*. (A, B) SDS-PAGE of membrane fractions from the following samples: (1) SIRV2-infected *S. islandicus*, 10 h.p.i.; (2) *E. coli*; (3) *E. coli* 1051 expressing SIRV2-ORF98. The positions of proteins with known molecular masses (in kDa) are indicated with bars. The asterisks (\*) show the bands containing P98. (A) Coomassie Blue-stained gel. (B) Western hybridisation of a duplicate of the gel A with antibodies against SIRV2-P98. (C, D) Thin sections through *E. coli* 1051 expressing SIRV2-P98 (scale bars, 200 nm).

**Figure 8:** Alignment of the protein sequence of the P98 protein of SIRV2 and the protein sequence of five P98 variants (TMD: transmembrane domain).

**Figure 9:** Heterologous expression of SIRV2-ORF98 in *Saccharomyces cerevisiae*. Thin sections through *S. Cerevisiae* expressing SIRV2-P98; scale bars, 1µm for (A) and (B), and 200 nm for (C).

**DETAILED DESCRIPTION**

The invention relates to a homomultimeric protein structure constituted by assembled monomers of the P98 protein of *Sulfolobus islandicus* rod-shaped virus 2 (SIRV2) or assembled monomer variants of said P98 protein.

5 The expression "*homomultimeric protein structure*" means that the claimed structure consists of multiple identical protein monomers, *i.e.*, that the structure results only from the assembly (or cluster) of identical protein monomers. In the described structure, the number of monomers is at least 100, at least 1000, at least 10000 or is comprised between 100 and 10000 or 100 and 1000. The expression  
10 "*homomultimeric*" encompasses not only the assembly of the structure by non covalent bonds (such as ionic bonds, hydrophobic interactions, hydrogen bonds and van der Waals forces) between identical monomers, but also the assembly of the structure by covalent bonds (such as peptide bonds) between identical monomers or the assembly of the structure by a combination of covalent and non covalent bonds  
15 between identical monomers. The homomultimeric protein structure does not as such comprise other protein or polypeptide components. In a particular embodiment, the homomultimeric protein structure does not comprise lipids or only a small proportion of lipids as compared to the number of monomers of the structure.

The protein monomer is selected from the group consisting of:

20 (a) the P98 protein of *Sulfolobus islandicus* rod-shaped virus 2 (SIRV2). The sequence of this P98 protein is given below and defined in SEQ ID NO:2: MAITLLEGALYGGFFAVTGILVGSFVVGGEIVHLYNEKQNNENFAKAVDQMSKSTVIAVE SIKDTTTTAINALLNMDTLRDVNALAREKAKDQNPNTQAK. The nucleic acid encoding the P98 protein is as defined in SEQ ID NO:1;

25 (b) a variant of the P98 protein of SIRV2 (of SEQ ID NO:2), obtained by deletion, addition or substitution of one or more of its amino acid residues, provided that said variant is still able to build the homomultimeric protein structure. In a particular embodiment, the number of substituted, deleted and/or added amino acid residues is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In a particular embodiment, the amino acid  
30 sequence of the variant is at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90% or at least 95% similar to SEQ ID NO:2. In the present application, similarity is calculated over the entire length of the longer of the two

aligned sequences (as an example, a variant with 90% similarity to SEQ ID NO:2 encompasses a variant the size of which is identical to SEQ ID NO:2 and having 10% substitutions as compared to SEQ ID NO:2, a variant the size of which is at most 10% longer than the size of SEQ ID NO:2, and a variant the size of which is at most 10% shorter than the size of SEQ ID NO:2). In a particular embodiment, the variant is obtained by substitution, preferably conservative substitution, of 1 to 10 residues, preferably 1 to 5 residues, preferably 1, 2, 3, 4 or 5, in SEQ ID NO:2. In a particular embodiment, the variant is obtained by amino acid substitution, and its sequence is at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90% or at least 95% similar to SEQ ID NO:2. In a particular embodiment, the variant comprises a transmembrane domain. Within the present application, a transmembrane domain is defined as a peptide domain rich in hydrophobic residues (A, G, P, L, I and/or V), organized in one or several hydrophobic  $\alpha$ -helix(es) and/or the interactions of which with a lipid layer are stable, such as the polypeptide comprising or consisting of the sequence identified by "TMD" in Figure 8 (for example, amino acid residues 10 to 30 of SEQ ID NO:2). The variant protein as defined above, is either natural (*i.e.*, found in another virus) or artificial (*i.e.*, not natural). Examples of P98 variants which may be used within the present invention comprise or consist of the amino acid sequences defined in SEQ ID NOs: 3 to 7. The person skilled in the art may determine which amino acid residue(s) may be substituted or deleted, the site of insertion of residue(s) or the nature of the substituting residue(s), based on the alignment of the sequences SEQ ID NO:2 to SEQ ID NO:7 (Figure 8), and in particular based on the alignment of the sequences SEQ ID NO:2 to SEQ ID NO:5. In a particular embodiment, the P98 variant is one of SEQ ID NO:2 to 7 in which at least one cysteine residue(s) (preferably one) has been inserted within the protein or at one of the extremities of the protein, provided this variant is still able to build the homomultimeric protein structure. The ability for a P98 variant to form the homomultimeric protein structure may be easily tested by expressing the nucleic acid encoding this variant from a plasmid, which is transfected in *Sulfolobus* or in *Escherichia coli* and by determining whether the transfected cells produce or not the homomultimeric protein structure of the invention;

(c) a chimeric polypeptide comprising or consisting of the C-terminal part of the P98 protein of SIRV2 (of SEQ ID NO:2), in particular from residues 31 to 98 of SEQ ID NO:2, or a variant thereof, fused to a transmembrane domain from a different protein. By "*chimeric*", it is meant that the polypeptide comprises or consists of several domains (at least 2, preferably 2, 3 or 4), originating from different proteins, the C-terminal part or domain being from the P98 protein of SIRV2 or being a variant of the P98 protein of SIRV2 as defined below. In a particular embodiment, the C-terminal part or domain is from the P98 protein of SIRV2 and/or is a polypeptide consisting of residues 31 to 98 of SEQ ID NO:2. The expression "*fused to*", as defined in the present application, means that the different parts or domains of the polypeptide or monomer of the invention are genetically fused, *i.e.*, linked by a peptide bond. The different parts or domains of the monomer or polypeptide of the invention may be either directly or indirectly (*e.g.*, genetically) fused. By "*directly fused*", it is meant that the last C-terminal residue of a part or domain of the monomer or polypeptide is linked by a peptide bond to the first N-terminal residue of another part or domain of the monomer or polypeptide. In contrast, by "*indirectly fused*", it is meant that the last C-terminal residue of a part of the monomer or polypeptide is linked by a peptide bond to the first N-terminal residue of a peptide linker, the last C-terminal residue of which is linked to the first N-terminal residue of another part of the monomer or polypeptide. In a particular embodiment, the sequence of the peptide linker is different from the residues which follow the transmembrane domain and different from the residues which precede the C-terminal part or domain, found in their respective proteins of origin. In a particular embodiment, the C-terminal part of the P98 protein of SIRV2, in particular residues 31 to 98 of SEQ ID NO:2, is C-terminal to the transmembrane domain. In an embodiment, the last C-terminal residue of the transmembrane domain is linked by a peptide bond to the first N-terminal residue of the C-terminal part or domain of the P98 protein of SIRV2 (or variant). In another embodiment, the last C-terminal residue of the transmembrane domain is linked by a peptide bond to the first N-terminal residue of a peptide linker, the last C-terminal residue of which is linked to the first N-terminal residue of the C-terminal part or domain of the P98 protein of SIRV2 (or variant); the transmembrane domain is as defined in point (b) above. A particular transmembrane domain is the



one of the Leader Peptidase (LEP) of *E. coli* consisting of sequence WLETGASVFPVLAIVLIV (SEQ ID NO:8); and

(d) the protein monomer as defined in (a) or a variant as defined in (b) or a chimeric polypeptide as defined in (c), fused to a signal sequence (or signal peptide).

5 In a particular embodiment, the signal sequence is genetically fused to the sequence of the protein monomer (P98 monomer or variant or chimeric polypeptide), *i.e.*, the signal sequence is either, preferably, N-terminal to the protein monomer or C-terminal to the protein monomer. The signal sequence is defined as a peptide the size of which is from 10 to 25 amino acid residues and is able to target the protein  
10 monomer into a compartment. By “*compartment*”, it is meant any subcellular structure surrounded by lipid layer, in particular by lipid bilayer, such as the cytoplasm, the nucleus, the mitochondria (intermembrane space or matrix), the chloroplast, the endoplasmic reticulum, the Golgi apparatus or cellular vesicles (*i.e.*, endosome, lysosome or vacuole). In an embodiment, the signal sequence is not  
15 cleaved once the protein monomer has been targeted into the selected compartment, and for this purpose the signal sequence is fused provided that the self-assembly of the protein monomers is not altered; the ability for a P98 variant to form the homomultimeric protein structure may be easily tested by expressing the nucleic acid encoding this variant from a plasmid, which is transfected into *Sulfolobus* or in  
20 *Escherichia coli* and by determining whether the transfected cells produce or not the homomultimeric protein structure of the invention. When the signal sequence is cleaved once the protein monomer has been targeted into the selected compartment, the resulting protein monomer, within the homomultimeric protein structure, is as defined in (a), (b) or (c) above.

25 The homomultimeric protein structure is built naturally by assembly of the P98 protein of SIRV2 (or its variants or fused to a signal sequence or as a chimeric polypeptide), *i.e.*, the P98 protein of SIRV2 is sufficient as a unique type of building unit to form the homomultimeric protein structure. This is confirmed by the examples which show that the homomultimeric protein structure is formed not only in an  
30 archaeon (*Sulfolobus acidocaldarius*) but also in particular in the bacteria *Escherichia coli* and in yeast *Saccharomyces cerevisiae*. Therefore, the homomultimeric protein structure may be obtained by expression of the nucleic acid encoding the P98 protein

of SIRV2 (or its variants or fused to a signal sequence or as a chimeric polypeptide) in a cell or cell culture. In a particular embodiment, the expression of the nucleic acid encoding the P98 protein of SIRV2 (or its variants or fused to a signal sequence or as a chimeric polypeptide) is carried out in archaeon (such as a *Sulfolobus strain*, for example *Sulfolobus acidocaldarius*), in a prokaryote (such as bacteria, for example *E. coli*) or in an eukaryote cell, such as a yeast (for example *Saccharomyces cerevisiae*), or higher eukaryotes, including a plant cell and an animal cell, preferably a cell of vertebrate, preferably a mammalian cell, more preferably a human cell. The expression of the nucleic acid encoding the P98 protein of SIRV2 (or its variants or fused to a signal sequence) may be obtained from an expression vector (such as a plasmid) or from the cell genome into which the nucleic acid is inserted, possibly after codon optimization to improve expression in selected cells. In a particular embodiment, the homomultimeric protein structure may be obtained by expression of the nucleic acid encoding the P98 protein of SIRV2 or the variants or the chimeric polypeptide, fused to a signal sequence, said homomultimeric protein structure being constituted by monomers of P98 protein of SIRV2 or of variants or of chimeric polypeptide, lacking the signal peptide, following the cleavage of the signal peptide after the monomer has been targeted into the selected compartment. Alternatively, the homomultimeric protein structure may also be obtained *in vitro* in solution in appropriate conditions by assembly of the P98 proteins (or variants or fused to a signal sequence or as a chimeric polypeptide).

The ability to give rise to a homomultimeric protein structure by the self-assembly of the P98 protein of SIRV2 (or its variants or fused to a signal sequence or as a chimeric polypeptide) is a property of the protein sequence of the P98 protein of SIRV2 (or its variants or fused to a signal sequence or as a chimeric polypeptide), *i.e.*, that the P98 protein of SIRV2 (or its variants or fused to a signal sequence or as a chimeric polypeptide) spontaneously self-assembles to adopt this homomultimeric protein structure. In a particular embodiment, this homomultimeric protein structure has a seven-fold rotational symmetry.

This homomultimeric protein structure consists of seven isosceles triangles, the area of which is constituted by assembled monomers of the P98 protein of SIRV2 or assembled monomer variant of the P98 protein, the base of each of these isosceles

triangles forming the sides of a regular heptagon. The homomultimeric protein structure has thus a heptagonal basis (formed of P98 proteins), each side of this heptagon being also the base of the isosceles triangles.

The heptagonal basis of the structure is empty or hollow. The heptagonal basis is regular, *i.e.*, all sides and all angles are slightly equal, *i.e.*, each angle of the heptagon is comprised between 125 and 132° and is especially about  $128.5^\circ \pm 2^\circ$ . Though all sides of the heptagon are substantially identical in length, the length of all sides of the regular heptagon may vary together thus enabling variation of the size of the entire structure. Accordingly, the size of the sides of the heptagon is comprised  
10 between 15 and 175 nm, preferably between 20 and 100 nm.

Each isosceles triangle is formed of P98 proteins, and in contrast to the heptagonal basis, its area is completely constituted of assembled P98 proteins, *i.e.*, the isosceles triangles are full. In a particular embodiment, the angle of the main vertex (*i.e.*, the angle formed by the meet of the two equal sides of the triangle) of each isosceles triangles is comprises between 29 and 35° and is about  $32^\circ \pm 3^\circ$  (the two remaining angles are identical and are thus about  $74^\circ \pm 8^\circ$ ).  
15

It is noteworthy that the geometry of the homomultimeric protein structure does not change over the course of formation of the structure, and over the growth of the structure which is achieved via gradual expansion of the triangular faces.

In a first embodiment, the homomultimeric protein structure is a pyramid with 7 identical isosceles triangular faces and with a hollow base, *i.e.*, is a baseless pyramid with 7 identical isosceles triangular faces (Figure 5C). In this conformation, the vertices of the isosceles triangular faces are connected or linked to each other, and accordingly close the structure. Thus, one of the equal sides of each isosceles triangular face is connected, two by two, to the equal side of the immediately adjacent isosceles triangular face. The structure in pyramid can also be viewed as a closed conformation. In a particular embodiment, the baseless 7-face pyramid has a diameter ranging from 30 to 250 nm, preferably 40 to 200 nm. Whatever the diameter or size of the homomultimeric protein structure, its base keeps its regular heptagonal shape and isosceles triangular faces. In a particular embodiment, the angle formed  
25  
30 between each triangular face and the empty heptagonal basis is comprised between 50 and 56 and is about  $53.5^\circ \pm 2^\circ$ .

In another embodiment, the homomultimeric protein structure has an open conformation, *i.e.*, that the vortex of each isosceles triangle is free (not connected to another vertex). Because of its particular shape, the homomultimeric protein structure in an open confirmation may have a diameter larger than the diameter of the  
5 baseless 7-face pyramid, that can exceed 250 nm. An example of a homomultimeric protein structure of the invention in an open conformation is disclosed in Figure 1F.

The homomultimeric protein structure of the invention, whatever its conformation, but preferably under the form of baseless 7-face pyramid, is very stable, when submitted to conditions comprising from moderate to extremely high  
10 temperatures and/or from neutral to extremely acidic pH. Thus, the homomultimeric protein structure is stable at a temperature as high as 80 °C and/or stable at a pH as low as pH2.

The ease to produce the homomultimeric protein structure of the invention combined to its stability at extreme temperature and/or pH, makes this structure an  
15 excellent tool to study protein-protein interaction in membranes such as cell membranes, such as cell membranes, as well as to modify the structure of the cell membrane and to expose heterologous molecule(s).

Thus, the invention also relates to a conjugate comprising or consisting of a  
20 homomultimeric protein structure of the invention, preferably the baseless 7-face pyramid, to which one or more heterologous molecule(s) is attached. By "*one or more*", it is meant that either only one molecule is attached to the homomultimeric protein structure, that many copies of the same heterologous molecule are attached to the homomultimeric protein structure or in contrast that distinct (different)  
25 heterologous molecules are attached, each in one copy or in many copies, to the homomultimeric protein structure. The term "*molecule*" encompasses drug, protein, polypeptide, nucleic acid (DNA, RNA, siRNA) or chemical compound. By "*heterologous*", it is meant any molecule as defined herein which is not the P98 protein or a variant as defined in the present application. The attachment of the  
30 heterologous molecule to the homomultimeric protein structure (in particular the P98 protein or variant) is either covalent (peptide bonds) or non-covalent (ionic bonds, hydrophobic interactions, hydrogen bonds and van der Waals forces). In the absence

of cysteine residue in the protein sequence of the P98 protein, the heterologous molecule may be attached, by disulfide bonds, to a P98 variant (as defined above) in which at least one cysteine residue(s) (preferably one) has been inserted within the protein or at one of the extremities of the protein. Thus, the homomultimeric protein structure of the invention is used as an anchor for the one or more heterologous molecule(s). In a particular embodiment of the invention, not all P98 proteins (or variants), constituting the homomultimeric protein structure of the invention, bear heterologous molecule(s). Thus, in a particular embodiment, less than 50%, less than 40%, less than, 30%, less than 20% or less than 10% of the P98 proteins (or variants) bear heterologous molecule(s). In another particular embodiment, when the homomultimeric protein structure is a baseless 7-face pyramid, the heterologous molecule(s) is attached to the apex of the pyramid, in particular on the part of the pyramid which is exposed out of the lipid layer or bilayer, in particular out of the cell lipid membrane. The heterologous molecules may be attached to the homomultimeric protein structure (in particular the P98 protein or variant or fused to a signal sequence or as a chimeric polypeptide) either before the assembly of the P98 proteins (or variants or fused to a signal sequence or as a chimeric polypeptide), during the assembly of the P98 proteins (or variants or fused to a signal sequence or as a chimeric polypeptide), or once the homomultimeric protein structure is assembled. In particular, the high stability of the homomultimeric protein structure of the invention enables the attachment of the heterologous molecule(s) once the structure is assembled, in various conditions, without denaturing or altering the resulting homomultimeric protein structure.

Thus, the invention also relates to the use of the homomultimeric protein structure of the invention, preferably the baseless 7-face pyramid structure, or a conjugate as defined herein, to insert into or to expose said homomultimeric protein or conjugate at the surface of a lipid layer, in particular of a lipid bilayer. Thus, the invention relates to a lipid layer, in particular a lipid bilayer, comprising inserted into the layer (or bilayer) or exposed on its surface, a homomultimeric protein structure or one or several conjugate(s) of the invention. By "*one or several conjugate(s)*", it is meant that either only one conjugate is inserted into or exposed on the lipid layer (or

bilayer), that many copies of the same conjugate are inserted into or exposed on the lipid layer (or bilayer) or in contrast that distinct (different) conjugates are inserted into or exposed on the lipid layer (or bilayer), each in one copy or in many copies. The difference between conjugates originate especially from the nature, composition  
5 or number of heterologous molecule(s) anchored or associated on the homomultimeric protein structure.

The lipid layer or lipid bilayer may be artificial or may be extracted from a cell membrane as a fragment.

In a particular embodiment, the homomultimeric protein structure of the  
10 invention, preferably the baseless 7-face pyramid structure, or conjugate of the invention, is inserted into or is exposed at the surface of a model lipid layer, *i.e.*, an artificially created lipid layer. Well known model lipid layers are black lipid membranes (BLM), supported lipid bilayers (SLB), the tethered bilayer lipid membrane (t-BLM) and vesicles.

15 Thus, the invention relates to a membrane microarray, in particular a cell membrane microarray, which comprises a solid support and a fluid supported lipid bilayer, wherein said bilayer comprises the homomultimeric protein structure or conjugate of the invention. Examples of solid supports are surfaces composed of or based on materials such as metal, metal oxides or mineral materials, especially gold,  
20 glass, diamond, silicon, silicon dioxide ( $\text{SiO}_2$ ), silicon nitride, tantalum pentoxide ( $\text{Ta}_2\text{O}_5$ ), titanium dioxide ( $\text{TiO}_2$ ), titanium nitride, titanium carbide, platinum, tungsten, aluminium or indium oxide, or mixtures thereof. In a particular embodiment, the surface is functionalized, *i.e.*, coated with a mixture of molecules able to interact,  
25 as phospholipids or specific ligands).

The invention also concerns biomimetic artificial membrane comprising a semipermeable membrane for supporting a lipid membrane and a lipid membrane comprising a plurality of lipid molecules arranged in a layer or bilayer, wherein said layer or bilayer comprises the homomultimeric protein structure or conjugate of the  
30 invention. In a particular embodiment, the supporting membrane is a porous polymer, silicon or graphene membrane.

In a particular embodiment, the invention also relates to a vesicle, in particular artificial vesicle, such as a micelle, bicelle, nanodisc or liposome, comprising inserted in the layer (or bilayer) or exposed on its surface a homomultimeric protein structure or conjugate of the invention. In a particular embodiment, when said homomultimeric  
5 protein structure is a baseless 7-face pyramid or a conjugate obtained from a baseless 7-face pyramid, the basis of the pyramid is in the lipid layer or bilayer and the apex of the pyramid is outside of the lipid layer or bilayer.

A lipid layer, lipid bilayer or model lipid layer of the invention may be used to assay *in vitro* molecule-molecule interactions, especially protein-protein interactions,  
10 in particular with the heterologous molecule(s) attached to the homomultimeric protein structure of the conjugate. Thus, the application relates to a process to assay *in vitro* molecule-molecule interactions, especially protein-protein interactions, comprising: (a) putting a lipid layer, in particular a lipid bilayer, comprising inserted into the layer (or bilayer) or exposed on its surface, a homomultimeric protein  
15 structure or conjugate(s) of the invention in contact with a solution to assay (comprising unidentified molecules); and (b) determining whether a molecule of this solution is able to interact with the homomultimeric protein structure or with the heterologous molecule(s) of the conjugate(s) of the invention. The invention also relates to a process to assay *in vitro* molecule-molecule interactions, especially  
20 protein-protein interactions, comprising: (a) putting a lipid layer, in particular a lipid bilayer, comprising inserted into the layer (or bilayer) or exposed on its surface, a homomultimeric protein structure or conjugate(s) of the invention in contact with a known molecule; and (b) determining whether this known molecule is able to interact with the homomultimeric protein structure or with the heterologous molecule of the  
25 conjugate of the invention. These two processes are particularly interesting to assay interactions between a receptor, particularly a transmembrane receptor and known or unidentified ligands. The homomultimeric protein structure of the invention being highly stable, it is possible to carry out step (b) by isolating the homomultimeric protein structure from the layer, bilayer or membrane cell and by analysing, with  
30 conventional techniques, the molecule(s) which interact(s) with this structure or with the heterologous molecule of the conjugate.

The invention also relates to the use of a lipid layer, lipid bilayer or model lipid layer of the invention to analyze the genome, a transcriptome, a proteome or a metabolome, using conjugate(s) of the invention wherein the heterologous molecule is respectively a DNA probe, a protein-based prey or a drug candidate prey. By  
5 “*transcriptome*”, it is meant a set of RNA, including mRNA, rRNA, tRNA, and other non-coding RNA, in particular mRNA. By “*proteome*”, it is meant a set of proteins and/or polypeptides. By “*metabolome*”, it is meant a set of metabolites such as metabolic intermediates, hormones and other signalling molecules, and secondary metabolites. Transcriptome, proteome and metabolome may be determined for a cell,  
10 a cell population, a cell type (organ-specific, tumor cells), a pathogen, a virus, a sample (plasma, blood), ...

Thus, the invention concerns a method (or process) to analyze the genome or a transcriptome of a cell, a cell population, a cell type or a sample, comprising:

(a) putting a lipid layer, in particular a lipid bilayer, comprising inserted into the  
15 layer (or bilayer) or exposed on its surface, conjugate(s) of the invention wherein said heterologous molecule is a nucleic acid (*e.g.*, DNA) probe, in contact with a DNA or RNA preparation (in particular a mRNA preparation) from a cell, a cell population, a cell type or a sample; and

(b) determining the RNA molecules, that interact (*e.g.*, hybridize) with the  
20 probes of the conjugate(s), to define the genome or the transcriptome of said cell, cell population, cell type or said sample, or to define a fingerprint thereof.

Thus, the invention is also directed to a method (or process) to analyze a proteome of a cell, a cell population, a cell type, a pathogen, a virus or a sample, comprising:

(a) putting a lipid layer, in particular a lipid bilayer, comprising inserted into the  
25 layer (or bilayer) or exposed on its surface, conjugate(s) of the invention wherein said heterologous molecule is a protein-based prey or drug candidate prey, in contact with a protein preparation from a cell, a cell population, a cell type, a pathogen, a virus or a sample; and

(b) determining the proteins, that interact with the preys of the conjugate(s), to  
30 define the proteome of said cell, cell population, cell type, a pathogen, virus or sample, or to define a fingerprint thereof.



Thus, the invention is also directed to a method (or process) to analyze a metabolome of a cell, a cell population, a cell type or a sample, comprising:

(a) putting a lipid layer, in particular a lipid bilayer, comprising inserted into the layer (or bilayer) or exposed on its surface, conjugate(s) of the invention wherein said  
5 heterologous molecule is a protein-based prey or drug candidate prey, in contact with a preparation from a cell, a cell population, a cell type or a sample; and

(b) determining the metabolites, that interact with the preys of the conjugate(s), to define the metabolome of said cell, cell population, cell type or sample, or to define a fingerprint thereof.

10 Another application concerns the vesicle, micelle, bicelle, nanodisc or liposome as defined herein which may be used to transport and possibly to expose *in vivo* the heterologous molecule(s) attached to the homomultimeric protein structure of the conjugate. Thus, the application also relates to a vesicle, micelle, bicelle, nanodisc or liposome as defined herein, for use as a medicament. In particular, the vesicle,  
15 micelle, bicelle, nanodisc or liposome comprising inserted into its layer (or bilayer) a conjugate as defined herein, more particularly a conjugate comprising a biologically active molecule as a heterologous molecule.

The invention also relates to a cell (or cell population), in particular an isolated cell or a cultured cell, expressing, in or on one of its membranes, the homomultimeric  
20 protein structure or the conjugate of the invention. By "*membrane*" of a cell, it is meant the outer (cell) membrane, or intracellular membranes including the nuclear membrane (or nuclear envelope), the mitochondria membrane (inner or outer), the chloroplast membrane, the endoplasmic reticulum membrane, the Golgi membrane or the membrane of cellular vesicles (*i.e.*, endosome, lysosome or vacuole).

25 In a particular embodiment, the cell is a non-archaea cell. In a particular embodiment, the cell is a prokaryotic cell (such as bacteria, for example *E. coli*) or an eukaryotic cell, such as a yeast (for example *Saccharomyces cerevisiae*), a plant cell, an animal cell, preferably a mammalian cell, more preferably a human cell.

In a particular embodiment, the protein monomer forming the homomultimeric  
30 protein structure or the conjugate of the invention is the P98 monomer (or P98 variant or chimeric polypeptide), expressed from a nucleic acid encoding the P98 monomer or a variant thereof or a chimeric polypeptide, fused to a signal sequence

as defined above, the fused signal sequence enabling the targeting of the protein monomer into the sought compartment, and being cleaved once the targeting is achieved.

5 These cells, in particular cells expressing in their membrane or exposing on the surface of their membrane a conjugate of the invention, can be used to *in vitro* study the cell membrane, the cell membrane dynamics or the interactions of cell membrane proteins. These cells may also be used to transport and to expose *in vivo* the heterologous molecule(s) attached to the homomultimeric protein structure (as conjugate). Thus, the application also relates to a cell as defined in the invention for  
10 use as a medicament. In particular, the cell comprising inserted in or one of its membrane a conjugate as defined herein, more particularly a conjugate comprising a biologically active molecule as a heterologous molecule.

The invention also relates to a transmembrane domain (TMD) consisting of residues 10 to 30 of SEQ NO NO:2 and variants thereof. The sequence of the  
15 variants is at least 70%, at least 80% or at least 90% similar to the sequence consisting of residues 10 to 30 of SEQ ID NO:2, either by substitution, deletion and/or addition. In a particular embodiment, the TMD variant differs from the TMD consisting of residues 10 to 30 of SEQ ID NO:2, by 1, 2, 3, 4 or 5 (preferably conservative) substitutions. The invention also relates to the use of a transmembrane  
20 domain or TMD variant as defined in the invention for the design and/or the preparation of a protein monomer having the ability to form, by self assembly, homomultimeric protein structure of the invention. In a particular embodiment, the protein monomer is from 80 to 110, in particular 90 to 100, amino acid residues in length.

25 The invention is also directed to a polypeptide consisting of the C-terminal part or domain of the P98 protein of SIRV2, *i.e.* a fragment of the P98 protein of SIRV2, in particular the domain consisting of residues 31 to 98 of SEQ ID NO:2, or a variant thereof. The invention also concerns a polypeptide comprising the C-terminal part or domain of the P98 protein of SIRV2, in particular the domain consisting of residues  
30 31 to 98 of SEQ ID NO:2, or a variant thereof, provided that said polypeptide is not the SIRV-2 protein of SEQ ID NO:2. The sequence of the variant of the C-terminal part or domain of the P98 protein of SIRV2 is at least 80%, at least 85%, at least

90% or at least 95% similar to the P98 protein of SIRV2, in particular to residues 31 to 98 of SEQ ID NO:2, provided that this variant is still able to build the homomultimeric protein structure of the invention when fused with a transmembrane domain (for example the transmembrane domain consisting of residues 10 to 30 of SEQ ID NO:2). In a particular embodiment, the variant is obtained by substitution, preferably conservative substitution, of 1 to 10 residues, preferably 1 to 5 residues, preferably 1, 2, 3, 4 or 5, in the polypeptide consisting of residues 31 to 98 of SEQ ID NO:2. Examples of variants of the C-terminal part of the P98 protein of SIRV2 are polypeptides comprising or consisting of amino acids 31 to 98 of SEQ ID NOs: 3 to 5, provided that these variants are not SEQ ID NO:3 to NO:5 respectively. The person skilled in the art may determine the site and nature of the substituting residue(s), based on the alignment of the C-terminal part of the sequences SEQ ID NO:2 to SEQ ID NO:5 (Figure 8).

The invention also relates to a chimeric polypeptide comprising or consisting of a transmembrane domain as defined herein, in particular other than a domain consisting of residues 10 to 30 of SEQ ID NO:2, fused, directly or indirectly, to the C-terminal part of the P98 protein of SIRV2 or a variant thereof, said chimeric polypeptide having the ability to form, by self assembly, homomultimeric protein structure of the invention. In a particular embodiment, said chimeric polypeptide is not the SIRV-2 protein of SEQ ID NO:2 and/or is not the polypeptide as defined in SEQ ID NO:3 to 5 and/or as defined in SEQ ID NO: 6 and 7. In a particular embodiment, this transmembrane domain is the transmembrane domain of the Leader Peptidase of *E. coli* as defined in SEQ ID NO:8. In a particular embodiment, the chimeric polypeptide monomer is from 80 to 110, in particular 90 to 100, amino acid residues in length. The invention also relates to the use of the C-terminal part of the P98 protein of SIRV2 or a variant thereof, for the design and/or the preparation of a chimeric polypeptide monomer comprising or consisting of a transmembrane domain fused directly or indirectly to this C-terminal part of the P98 protein of SIRV2 or a variant thereof, said chimeric polypeptide monomer having the ability to form, by self assembly, homomultimeric protein structure of the invention. The features described in paragraph (c) above regarding the definition of the protein monomer apply to the definition of the chimeric polypeptide as such and its use.

## EXAMPLES

### A) Materials and Methods

5       **Virus and host strains.** The stock of the SIRV2 virus was prepared as described in ref. 2. The growth of *S. islandicus* LAL/14 and virus infection were also described in ref. 2.

10       **VAP isolation.** *S. islandicus* LAL 14/1 cells infected with SIRV2 and uninfected controls were harvested 10 h.p.i (hour post infection). The cells were disrupted using a French press, and the membranes were collected by centrifugation at 100,000 g as described in ref. 4. VAPs were isolated from the membrane fraction using anti-P98 antibody. The customised P98 polyclonal peptide antibody was raised in rabbit against a peptide corresponding to the C-terminal region of P98 and affinity purified  
15 using this antigen (Eurogentec). The specificity of the antibody was tested on a Western blot. The antibodies were coupled to magnetic beads covered with protein A (Dynabeads Protein A, Invitrogen™) according to the manufacturer's protocol using non-denaturing elution. Alternatively, the membrane fraction was washed in 0.5% N-lauroylsarcosine (Sigma) and centrifuged at 100,000 g, and the pellet was used for  
20 immunoprecipitation.

25       **Protein and lipid analysis.** The protein fractions were loaded onto a 4-12% polyacrylamide Bis-Tris gradient gel (Invitrogen™) using 2-(N-morpholino) ethanesulphonic acid SDS running buffer (Invitrogen™), and the proteins were visualised using either SYPRO Ruby (Invitrogen™) or Coomassie-based Instant Blue™ (Expedeon) staining. The presence of lipids in the samples was detected by overnight staining in Sudan Black (Sigma-Aldrich) according to the manufacturer's protocol. MS analysis was performed as described in ref. 4. For Western hybridisation, proteins were transferred onto a PVDF membrane. P98 was visualised  
30 using 1:10000 dilution of the anti-P98 antibody and peroxidase-coupled goat anti-rabbit IgG (Sigma-Aldrich) and the SuperSignal® West Pico Chemiluminescent Substrate (Thermo Scientific) on Amersham Hyperfilm™ ECL (GE Healthcare).

**Negative contrast EM and immunolabelling of isolated VAPs.** Purified VAPs were absorbed to glow discharged carbon-coated grids and negatively stained for 1 min with 2% (wt/vol) uranyl acetate. For immunocytochemistry, after absorption on the grids, the samples were incubated in PBS with 1% BSA and labelled with the anti-P98 peptide antibody. The antibody-labelled protein was detected using 10-nm Protein A-colloidal gold (CMC, The Netherlands). All samples were observed on a Jeol 1200EX-II operated at 80 kV. Images were recorded and measured on a MegaView or KeenView camera (SIS, Japan) using the ITEM software version 5.0 (SIS, Japan).

10

**Cryo-EM of isolated VAPs.** Purified VAPs were spread on glow discharged Quantifoil R2/2 grids (Quantifoil Micro Tools GmbH, Germany) and cryofixed in liquid ethane. The specimens were transferred to a Gatan 626 DH cryoholder (Gatan, USA) and examined on a Jeol2010F electron microscope (Jeol, Tokyo, Japan) operating at 200 kV. Images were recorded under low-dose conditions on a Gatan Ultrascan 4000 with Digital Micrograph (Gatan, USA) version 1.83.842.

15

**Immunolabelling of thawed cryosections.** SIRV2-infected *S. islandicus* cells were fixed 10 h.p.i. with 4% formaldehyde in 0.1 M HEPES buffer, pH 6, for 5 h at 4°C. The cells were pelleted by low speed centrifugation, embedded in 10% gelatine, cut into small blocks and infiltrated in 2.3 M sucrose at 4 °C. The blocks were mounted on aluminium pins and frozen in liquid nitrogen. Sections were cut with a nominal feed of 70 nm using a 35° angle diamond knife (Diamtome, Biel, Switzerland) and a FC6 microtome (Leica Microsystems, Vienna, Austria). To pick up the ultrathin cryosections, a 1:1 mixture of 2.3 M sucrose and 2% methylcellulose was used. Thawed sections were placed on formvar and carbon-coated copper grids, and sections were blocked in 1% BSA and labelled with the anti-P98 peptide antibody and 10-nm Protein A-colloidal gold (CMC, Utrecht, The Netherlands). Images were recorded on a KeenView camera (SIS, Japan) using the ITEM software version 5.0 (SIS, Japan).

20

25

30

**Resin embedding of *Sulfolobus* cells.** *S. acidocaldarius* MR31 pSVA1059 and SIRV2-infected *S. islandicus* were fixed with 2.5% (wt/vol) glutaraldehyde in 0.1 M HEPES buffer, pH 6 and 7, respectively. Post-fixation, dehydration, embedding in epoxy resin, sectioning and imaging with TEM were performed as described in ref. 2.

5

**High pressure freezing and freeze substitution of *E.coli*.** *E.coli* cells were taken up in capillary tubes (Leica, Vienna, Austria) as described in ref 9. The filled tube was placed into the cavity of a brass planchette (Agar Scientific, Stanstad, UK), filled with 1-hexadecen, and immediately frozen with a HPM 010 (BalTec, now Abra Fluid AG, Widnau, Switzerland). Freeze-substitution was performed in anhydrous acetone (EMS, Hatfield, USA) containing 2% osmium tetroxide (Merck, Darmstadt, Germany) and 2% water. Substitution was performed at -90 °C for 24h, and at -60 °C and -30 °C for 8h each in an automated freeze substitution device (Leica AFS, Leica Microsystems, Vienna, Austria). Afterwards the temperature was raised to 0 °C and the samples washed with dry acetone and embedded stepwise in Epon and polymerized at 60°C for 48h.

10

15

**Plasmid constructs and transformation of *S. acidocaldarius* and *E. coli*.**

For the overexpression of P98 in *S. acidocaldarius* M31, SIRV2-ORF98 (SEQ ID NO:2) was amplified from SIRV2 genomic DNA and cloned into the *lacS* gene locus in the pSVA5 plasmid (10) using the NcoI and BamHI sites. SIRV2-ORF98 and the *araS* promoter were transferred from pSVA5 to the pCMallacS plasmid (5) using the NcoI and EagI sites, which yielded pSVA1059. *S. acidocaldarius* M31 was transformed with pSVA1059. The preparation of competent cells, methylation of the plasmid, and electroporation were carried out as described in ref 1. The electroporator used was the Gene Pulser Xcell (Bio-Rad) with 1 mm cuvettes at 1500 V, 600 Ω and 25 μF. The cells were regenerated in Brock medium containing 0.1% enzymatically hydrolysed casein (tryptone, BD Biosciences) and 0.2% dextrin for 30 min at 75 °C. The cells were then streaked onto selective Gelrite® (Sigma) plates lacking uracil. After 5 days, a preculture was grown under selective conditions from a single colony; 50 mL of medium containing inducer (0.2% maltose) was then inoculated with 1 mL preculture and grown until an OD600 of 1 was reached. For the

20

25

30

overexpression of SIRV2-ORF98 in *E. coli* Rosetta(DE3)pLys (Novagen), the same gene was amplified from SIRV2 genomic DNA and cloned into the T7 promoter-driven expression vector pSA4 (6) using the NcoI and BamHI sites. The pSVA1051 vector contains an IPTG-inducible promoter that was used for the expression a C-  
5 terminal his-tagged protein.

#### **Plasmid constructs, transformation and EM of *S. cerevisiae***

For the overexpression of the SIRV2 P98 protein in *Saccharomyces cerevisiae*, SIRV2-ORF98 (SEQ ID NO:2) was amplified from SIRV2 genomic DNA and cloned  
10 into the expression vector pCM190 (Gari et al, 1997) using PstI and XbaI sites. Then the plasmid was transfected into *S. cerevisiae* according to the protocol described by Gari et al (Gari et al, 1997). After selection on plates without uracil, a single colony was picked and grown at 30 °C overnight in a pre-culture in selective medium without uracil, and with 10 µg/ml doxycyclin. The next day, cells were diluted 1/1000 in  
15 medium without doxycyclin. After 16 hours, cells were recovered by centrifugation and prepared for immunolabelling of thawed cryosections as described by Quax et al. (Quax et al, 2011).

#### **Plasmid constructs, transformation and EM of *E. coli***

For the overexpression of the SIRV2 P98 protein lacking the transmembrane  
20 domain in *Escherichia coli*, a fragment consisting of the 216 nucleotides coding for the C-terminal part of SIRV2-ORF98 (nucleotides 79 to 297 of SEQ ID NO:1, encoding residues 27 to 98 of SEQ ID NO:2) was amplified from SIRV2 genomic DNA. This fragment was cloned into the LacS gene locus in the T7 promoter-driven  
25 expression vector pSA4 plasmid (Albers et al, 2003)) using NcoI and BamHI sites for expression with a N-terminal his-tag. This plasmid was transfected into *E. coli* Rosetta (DE3) pLys (Novagen Merck). 3 hours post IPTG induction, the transfected cells were harvested and prepared for high pressure freezing and freeze substitution by the method as described by Quax et al. (Quax et al. 2011).

## B) Results

**VAP isolation.** The shape of the pyramidal egress structures VAPs, which were reported to be found on the surface of SIRV2-infected *S. islandicus* cells (2), suggested that they might represent individual structures. To test this hypothesis, we analysed the membrane fraction of infected cells that were disrupted using a French press. By transmission electron microscopy (TEM); it was observed for the first time numerous individual particles which had pyramidal shapes and heptagonal bases. The resemblance of their shape to that of VAPs observed *in vivo* supported the notion that VAPs represent autonomous structures. We isolated the particles using antibodies against protein 98 (P98) encoded by SIRV2, which we had previously postulated to be a constituent of the VAP (4). Polyclonal antibodies were fused to magnetic beads and used to bind VAPs in crude membrane extracts of infected cells collected 10 hours post infection (h.p.i.), which corresponds to the start of virion release. It was possible to precipitate and purify the VAPs in this manner. In the purified preparation, no structures other than VAPs were observed, except for a small proportion of S-layer fragments from the host cells. Moreover, the majority of the isolated structures appeared to be intact and similar in shape to the VAPs on the surface of the infected cells (2) (Fig. 1 A, B). The intact purified VAPs could either be observed from the top, which revealed the seven-fold rotational symmetry of the structure (Fig. 1A), or from the side, in which case only three to four of the seven triangular faces of the VAPs were visible (Fig. 1B). Along with the intact VAPs, in the purified preparation single triangular subunits were also found to be detached from the structure (Fig. 1C). In addition, a small proportion of the VAPs were present in an “open” conformation (Fig. 1D and E). Characteristically, in the latter case, the seven faces of the VAPs were not strictly triangular but rather were slightly curved (Fig. 1D and E) and resembled the structure of the VAP *in vivo* after it opens. To exclude the possibility that this curvature was an artefact of sample preparation for negative staining, the VAPs were analysed using cryo-EM. The faces of the open VAPs that were fixed in vitreous ice were also curved (Fig. 2A). The VAPs were best observed from the top, which revealed the heterogeneity of the diameter of the VAPs (Fig. 2B).



**VAP constituents.** The ability to isolate intact VAPs allowed studying their constituents. The protein composition of the VAPs was analysed by SDS-PAGE followed by SYPRO Ruby staining (Fig. 3A). The three visible bands in the purified VAP preparation were identified by Matrix-assisted laser desorption/ionisation (MALDI)-time-of-light (TOF) mass spectrometry (MS) and MS/MS analyses. The two larger proteins represented the light and heavy chains of the anti-P98 antibody used to purify the VAPs. The smallest protein (approximately 10 kDa, indicated by an asterisk) was identified as the product of SIRV2-ORF98 (SEQ ID NO:2) (Fig. 3A). To test the presence of phospholipids in the purified VAPs, a duplicate of the gel shown in Fig. 3A was stained using Sudan Black (Fig. 3B). Phospholipids could be observed in the membrane fraction and the first two washes of the precipitate but were not detectable in the purified VAP preparation.

**Immunolabelling of VAPs.** The localisation of SIRV2-P98 in the VAPs was verified by immuno-electron microscopy using polyclonal P98 antibodies and 10-nm protein A-gold particles (Fig. 4). The purified VAPs were labelled evenly across the structure, without concentration of the label in a particular area (Figs. 4A, B and C). As a control, similar labelling was performed on a crude membrane fraction of infected cells, which, in addition to VAPs, contained fragments of S-layers, membranes and virions. In this case, only VAPs were specifically labelled. Another control was performed by labelling purified VAPs with pre-immune serum and 10-nm protein A-gold particles. In this case, very low background labelling was observed. The specific localisation of P98 in the VAPs was also confirmed in *S. islandicus* cells infected with SIRV2 h.p.i. Thawed ultrathin cryo-sections of chemically fixed cells were immunolabelled. VAPs in the ultra-thin sections had either an heptagonal appearance if the section was in the plane parallel to the cell surface and the base of the VAP or a triangular appearance if the sections were in other planes (2). As a result of labelling, the gold particles were arranged in either a quasi-heptagonal shape (Fig. 4D) or along two sides of a VAP triangle (Fig. 4E). As a control, thawed ultra-thin cryo-sections of uninfected *S. islandicus* cells were labelled in a similar manner, and no labelling of any specific structure was observed.

**VAP structure.** Electron microscopy of isolated VAPs was used to produce a detailed description of their structure. Images of 150 intact or partially disrupted VAPs were measured. Independent of the sizes, the geometry of all VAPs was identical and represented a baseless pyramid with a heptagonal perimeter. Each of the seven  
5 faces of the pyramidal structure was an isosceles triangle, *i.e.*, two sides were equal in length. The two angles at the base of the pyramid were  $74^{\circ} \pm 8^{\circ}$ , and the one at the tip was  $32^{\circ} \pm 3^{\circ}$ . The structure shown in Fig. 5A represents a VAP in the closed form that was disrupted only along one seam between two of the seven faces. A two-dimensional schematic of the VAP is schematically presented in Fig. 5B, and folding  
10 of this sequences results in the three-dimensional structure shown in Fig. 5C. The structure perfectly matches all of the electron microscopic images of the VAPs taken from different angles. The data derived from isolated VAPs allowed concluding that the VAP is a baseless, hollow, pyramidal structure (Fig. 5C). This interpretation agrees with earlier reports of the structure of the VAP *in vivo*. Thin sections of  
15 infected cells suggest that cytoplasm is present in the interior of the VAP (Fig. S2A) (2).

The VAPs in the analysed preparation were isolated from a quasi-synchronous population of host cells 10 h.p.i., and although they had identical geometries, they differed significantly in size. The lengths of the sides of the regular heptagonal  
20 perimeter of the VAP were measured using 150 images of isolated closed structures and ranged from about 15 nm to about 175 nm. These structures were grouped into four size classes: (I) 0-50, (II) 50-100, (III) 100-150 and (IV) 150-200 nm. The following percentages of VAPs in each class were found: class I, 22%; class II, 25%; class III, 47%; and class IV, 7%. The most likely cause of the observed size  
25 distribution and the low percentage of class IV structures appears to be the proximity of the latter to the open state. This suggestion is based on the measurements of the side lengths of 20 open VAPs, of which 95% were in the range of 125-180 nm.

**Overexpression of SIRV2-ORF98 in *Sulfolobus acidocaldarius*.** Although  
30 P98 was found to be the sole constituent of the VAPs, it remained unclear whether it was sufficient for the formation of the pyramidal structure. To examine this possibility and to exclude the involvement of any other SIRV2-encoded factors in VAP

assembly, SIRV2-ORF98 was expressed heterologously in the hyperthermophilic archaeon *Sulfolobus acidocaldarius*. This member of the genus *Sulfolobus* is resistant to SIRV2 and does not carry any extrachromosomal element, or any genes homologous to those of SIRV2. For expression, SIRV2-ORF98 was cloned under the control of a maltose-inducible promoter in the pCMaILacS plasmid (5). The level of expression, estimated by Western hybridisation, was about 100-times lower than that produced by SIRV2 infection of *S. islandicus* (Figs. 6A and B). Remarkably, the analysis of ORF98-expressing *S. acidocaldarius* cells by electron microscopy showed the presence of VAPs on the cell membranes (Fig. 6C). The VAPs perforated the S-layer and were similar in size and geometry to the VAPs of SIRV2-infected *S. islandicus* cells. The low number of observed VAPs, *i.e.*, about 1 in 100 cells, corresponded to the low level of ORF98 expression in *S. acidocaldarius*. It is noteworthy that only closed VAPs were observed in the heterologous system, whereas in the natural virus-host system VAPs in both closed and open states are present (2,3).

**Overexpression of SIRV2-ORF98 in *Escherichia coli*.** To exclude the possibility that some proteins common to members of the genus *Sulfolobus* are involved in VAP formation and to further test the self-assembly capacity of P98, the SIRV2-ORF98 gene was expressed in *E. coli*. The gene was cloned under a *lacS* promoter into the pSA4 plasmid (6). Expression was confirmed by Western hybridization, and the efficiency of P98 production was comparable to that of SIRV2-infected *S. islandicus* cells (Figs. 7A and B). The presence of the recombinant P98 was detected primarily in the membrane fraction. Surprisingly, P98 was not only produced in *E. coli* but was also capable of forming VAPs in these cells. Electron microscopy analysis of thin sections of P98-expressing cells of *E. coli* at 3, 7 and 21 hours after induction, revealed the presence of many pyramidal structures on the inner membrane, which protruded into the periplasmic space of the cell (Fig. 7C and D). The VAPs appeared to be similar in size and shape to those observed on the cell surface of SIRV2-infected *S. islandicus* and SIRV2-ORF98 expressing *S. acidocaldarius* (Fig. 7C). Only closed VAPs were observed. Three hours after induction, the majority of cells contained VAPs; however, the cells stopped growing

almost immediately after induction, and the proportion of VAP-containing cells did not change significantly in the following 21 hours. In addition, the number of observed VAPs per cell did not change over time. The number of VAPs was generally very high and correlated with the expression levels of the viral gene. In most sections,  
5 more than 30 VAPs were observed per cell (Fig. 7D). The formation of VAPs seemed to increase the surface area of the inner membrane, and the distance between the outer and inner membranes (Figs. 7C and D).

### **Overexpression of SIRV2-ORF98 in *Saccharomyces cerevisiae***

10 In order to explore the capacity of the SIRV2 P98 protein to form VAPs in different lipid membranes, the protein was expressed in *Saccharomyces cerevisiae*. Expression of the SIRV2 P98 protein in *S. cerevisiae* resulted in VAP formation, in all cellular membranes as can be judged by electron microscopy of immunolabelled thawed cryosections (Fig. 9). Gold labelling of the SIRV2 P98 protein was specifically  
15 present on the nuclear envelope, endoplasmatic reticulum, golgi, intracellular vesicles and even mitochondria. In addition, VAP structures could be observed on these cellular membranes. VAPs are inserted in both directions in the intracellular membranes with the tip of the pyramids pointing either inwards or outwards. These results demonstrate that the SIRV2 P98 protein can self-assemble into VAPs, not  
20 only in prokaryote cells but also in membranes from eukaryotic cells.

### **Role of transmembrane domain of SIRV2-P98**

To elucidate the function of the different domains of the SIRV2 P98 protein, a truncated version of this protein, lacking the transmembrane domain, was expressed  
25 in *Escherichia coli*. Though the *E. coli* mutants expressing the SIRV2 P98 protein lacking the transmembrane domain did not differ in morphology from wild type *E. coli* cells using electron microscopy, *E. coli* mutants showed the presence of electron dense structures (aggregates) revealing that the SIRV2 P98 protein lacking the transmembrane domain is not able to form a pyramidal structure. These results  
30 indicate that the transmembrane domain of SIRV2-P98 is essential for the correct formation of VAPs. It is possible that the SIRV2-P98 transmembrane domain

contains intrinsic properties essential for pyramid formation, or that merely a transmembrane domain of whichever consistence is required.

## DISCUSSION

5        The discovery of the exceptional VAP-based virion egress system in Archaea (2, 3) has drawn attention to the underlying molecular machinery. The present finding that the VAPs represent separate structural units that can be isolated and purified from the membrane fraction of infected cells is crucial for understanding the nature and formation of these remarkable structures. Purification of VAPs was achieved by  
10 immunoprecipitation using antibodies against protein 98 of SIRV2, which was previously postulated to be a component of VAPs (4).

      The VAPs were isolated and purified from a quasi-synchronised culture of SIRV2-infected *S. islandicus* at the start of virion release. The majority of purified VAPs appeared to be intact. Each VAP was composed of seven faces of isosceles  
15 triangles that together formed a baseless pyramid. In all cases, the angles of the faces were  $74^{\circ} \pm 8^{\circ}$  and  $32^{\circ} \pm 3^{\circ}$ . However, the diameters of the VAPs were heterogeneous. This heterogeneity most likely reflects the dynamics of VAP development in the analysed cell culture. The observations suggest that VAP geometry does not change over the course of formation and that VAPs grow via  
20 gradual expansion of the triangular faces.

      In addition to VAPs in the natural closed conformation, the purified preparation contained VAPs that were in the open state (Fig. 1). These VAPs might have originated from perforated cells. Indeed, the population of infected cells that was used for VAP isolation contained a small proportion of perforated cells with open  
25 VAPs. Alternatively, "opening" of VAPs could have been caused by mechanical shearing during the purification process. The faces of VAPs in the open state were curved, most likely due to the characteristics of the opening process. Another characteristic feature of the open VAPs was their large size, with diameters exceeding 250 nm. This suggests that VAPs might need to reach certain dimensions  
30 before they can be opened.

      The analysis of the VAP constituents revealed that the structure is composed of multiple subunits of a SIRV2-encoded protein, SIRV2-P98. No lipid component could

be detected by the methods used. The absence or extremely low proportion of lipids agrees with the fact that VAPs could be isolated as intact structures after extensive washing of the membrane fraction with detergents (Materials and Methods).

SIRV2-P98 was confirmed to be the sole constituent of the VAP by  
5 heterologous expression experiments. Expression of SIRV2-ORF98 in *S. Acidocaldarius*, *E. coli* and *S. Cerivisiae* led to the formation of VAPs on cell membranes (Figs. 5, 6 and 9). These results demonstrate that P98 is capable of self-assembling into pyramidal structures with seven-fold rotational symmetry. The involvement of certain auxiliary proteins in VAP assembly can be excluded, ORF98  
10 being the only SIRV2 gene expressed in the *S. Acidocaldarius*, *E. coli* and *S. Cerivisiae*. Moreover the abundant presence of the SIRV2-P98 in all cellular membranes indicates that the protein is capable to self-insert into lipid layers without the requirement of additional transport systems or a signal peptide. It is remarkable that the dramatic differences in the membrane composition and chemistry between  
15 bacterial and archaeal cells (7) did not affect the self-assembly of recombinant P98 into VAPs *in vivo*. The ability of P98 to form VAPs under the different conditions required for the growth of an hyperthermophilic, extremely acidophilic archaeon, a mesophilic bacterium and a yeast is also remarkable. Finally, also unexpected, the formation of VAPs into the membranes of different eukaryotic cellular compartments,  
20 including outer membrane, nuclear envelope, endoplasmic reticulum membrane, Golgi membrane, membrane of vesicles and even in mitochondria membrane, enabling to conclude that the SIRV2 P98 protein is able to form pyramidal structures in most biological cells and most organellar membranes.

The VAPs formed by heterologous expression of SIRV2-ORF98 in *E. coli* and *S.*  
25 *acidocaldarius* were similar in size and shape to those formed in *S. islandicus* infected with SIRV2. However, in the heterologous systems, VAPs were never observed in the opened state, unlike in the natural system where VAPs eventually open and cause perforation of the infected cell. These observations suggest that at least one special factor is required for the process of VAP opening, which is absent in  
30 *S. acidocaldarius* and *E. coli*. The nature and origin, viral or cellular, of this factor is currently unclear.

Our results demonstrate that the rudivirus SIRV2 encodes one autonomous structure in addition to the capsid, i.e., the VAP. The virus-encoded constituents of both structures can self-assemble in both prokaryotes and eukaryotes. The major capsid protein self-assembles into filaments with the same diameter as the native  
5 linear virion (8), and VAP protein P98 self-assembles into pyramids. However, the functions of the two autonomous structures are different. Whereas the function of the former is DNA packaging and the formation of virus particles, the latter is specifically designed to release the virus particles from the host cell. To the best of our knowledge, the VAP represents the first example of a new class of non-capsid virus-  
10 encoded autonomous structures. The molecular simplicity and elegance of the VAP design revealed in this study should aid in the future analysis of the elaborate molecular mechanisms of the unique virion release system in Archaea.

## BIBLIOGRAPHY

- 15 1. Prangishvili, D., Forterre, P. & Garrett, R. A. (2006) *Nat Rev Microbiol* 4, 837-48.
2. Bize, A., Karlsson, E. A., Ekefjard, K., Quax, T. E., Pina, M., Prevost, M. C., Forterre, P., Tenailon, O., Bernander, R. & Prangishvili, D. (2009) *Proc Natl Acad Sci U S A* 106, 11306-11.
- 20 3. Brumfield, S. K., Ortmann, A. C., Ruigrok, V., Suci, P., Douglas, T. & Young, M. J. (2009) *J Virol* 83, 5964-70.
4. Quax, T. E., Krupovic, M., Lucas, S., Forterre, P. & Prangishvili, D. *Virology* 404, 1-4.
5. Berkner, S., Wlodkowski, A., Albers, S. V. & Lipps, G. *Extremophiles* 14, 249-  
25 59.
6. Albers, S. V., Szabo, Z. & Driessen, A. J. (2003) *J Bacteriol* 185, 3918-25.
7. van de Vossenberg, J. L., Driessen, A. J. & Konings, W. N. (1998) *Extremophiles* 2, 163-70.

8. Vestergaard, G., Shah, S. A., Bize, A., Reitberger, W., Reuter, M., Phan, H., Briegel, A., Rachel, R., Garrett, R. A. & Prangishvili, D. (2008) *J Bacteriol* 190, 6837-45.
- 5 9. Hohenberg H, Mannweiler K, Müller M (1994) High-pressure freezing of cell suspensions in cellulose capillary tubes. *J Microsc* 175:34-43
10. Albers SV, et al. (2006) Production of recombinant and tagged proteins in the hyperthermophilic archaeon *Sulfolobus solfataricus*. *Appl Environ Microbiol.* 72:102-111
- 10 11. Berkner S, Lipps G (2007) Characterization of the transcriptional activity of the cryptic plasmid pRN1 from *Sulfolobus islandicus* REN1H1 and regulation of its replication operon. *J Bacteriol.* 189:1711-21



**CLAIMS**

1. Homomultimeric protein structure constituted by assembled monomers of the P98 protein of *Sulfolobus islandicus* rod-shaped virus 2 (SIRV2), assembled monomer variants of said P98 protein or assembled chimeric polypeptides comprising or consisting of the C-terminal part of said SIRV2 P98 protein, or variant thereof, fused to a transmembrane domain.

2. Homomultimeric protein structure according to claim 1, which consists in seven isosceles triangles, the area of which is constituted by assembled monomers of the P98 protein of *Sulfolobus islandicus* rod-shaped virus 2 (SIRV2) or assembled monomer variant of said P98 protein, wherein the base of each of these isosceles triangles forms the sides of a regular heptagon, in particular wherein the angle of the main vertex of said isosceles triangles is about 32°.

3. Homomultimeric protein structure according to claim 1 or 2, wherein the structure is a pyramid with 7 identical isosceles triangular faces and with a hollow base.

4. Homomultimeric protein structure according to claim 1 or 2, wherein the structure is in an open conformation.

5. Homomultimeric protein structure according to any one of claims 1 to 4, obtained by expression of the nucleic acid encoding the P98 protein of *Sulfolobus islandicus* rod-shaped virus 2 (SIRV2) or encoding a variant of the p98 protein in a cell, in particular in *Sulfolobus acidocaldarius* or in *Escherichia coli*.

6. Conjugate comprising or consisting of a homomultimeric protein structure as defined in any one of claims 1 to 5, to which one or more heterologous molecule(s) is covalently or non-covalently attached.

7. Lipid layer, in particular lipid bilayer, comprising inserted in the layer (or bilayer) or exposed on its surface, a homomultimeric protein structure or conjugate as defined in any one of claims 1 to 6.

8. Lipid layer or bilayer according to claim 7, which is a model lipid layer, such as black lipid membranes (BLM), supported lipid bilayers (SLB), the tethered bilayer lipid membrane (t-BLM) and vesicles.

**9.** Vesicle according to claim 8, which is an artificial vesicle, such as a micelle, bicelle, nanodisc or liposome.

**10.** Non-archae cell, expressing, in one of its membranes, the homomultimeric protein structure or conjugate as defined in any one of claims 1 to 6, in particular a prokaryotic cell, such as bacteria, for example *E. coli*, or an eukaryotic cell, such as a yeast, a plant cell, an animal cell, preferably a mammalian cell, more preferably a human cell.

**11.** Lipid layer, lipid bilayer, vesicle or non-archaea cell according to any one of claims 7 to 10, wherein, when said homomultimeric protein structure is a baseless 7-face pyramid, wherein the basis of the pyramid is in the lipid layer or bilayer and the apex of the pyramid is outside of the lipid layer or bilayer.

**12.** Lipid layer, lipid bilayer, vesicle or non-archaea cell according to claim 11, wherein the one or more heterologous molecule(s) is attached to the apex of the baseless 7-face pyramid, and is exposed outside of the lipid layer, of the lipid bilayer or of the cell membrane.

**13.** Use of a lipid layer or lipid bilayer according to any one of claims 7, 8, 11 or 12 to *in vitro* assay molecule-molecule interaction protein-protein interaction, in particular with the heterologous molecule(s) attached to the homomultimeric protein structure of the conjugate, or to analyze the genome, a transcriptome, a proteome or a metabolome.

**14.** Use of cell according to any one of claims 10 to 12, to *in vitro* study the cell membrane, the cell membrane dynamics or the interactions of cell membrane proteins.

**15.** Use of a micelle, bicelle, nanodisc, liposome or a non-archaea cell according to any one of claims 9 to 12 to transport and/or to expose *in vivo* the heterologous molecule(s) attached to the homomultimeric protein structure of the conjugate.

**16.** A chimeric polypeptide comprising or consisting of a transmembrane domain fused, directly or indirectly, to the C-terminal part of the P98 protein of SIRV2 or a variant thereof, said chimeric polypeptide having the ability to form, by self

assembly, a homomultimeric protein structure according to any one of claims 1 to 5, provided that said chimeric polypeptide is not the SIRV-2 protein of SEQ ID NO:2 and is not the polypeptide as defined in SEQ ID NO: 3 to 7..

**17.** Use of a transmembrane domain consisting of residues 10 to 30 of SEQ ID NO:2 or a transmembrane domain variant thereof, for the design and/or the preparation of a protein monomer having the ability to form, by self assembly, a homomultimeric protein structure according to any one of claims 1 to 5.




Fig. 1




Fig. 2




Fig. 3




Fig. 4

4/7




Fig. 5




Fig. 6




Fig. 7





Fig. 8



A.



B.




Fig. 9

C.




Fig. 9

INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2012/050902

A. CLASSIFICATION OF SUBJECT MATTER  
INV. C07K14/01 B82Y5/00  
ADD.  
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED  
Minimum documentation searched (classification system followed by classification symbols)  
C07K B82Y  
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>QUAX TESSA E F ET AL: "The Sulfolobus rod-shaped virus 2 encodes a prominent structural component of the unique virion release system in Archaea.", VIROLOGY, vol. 404, no. 1, 15 August 2010 (2010-08-15), pages 1-4, XP002639048, ISSN: 1096-0341 cited in the application the whole document figure 1</p> <p style="text-align: center;">----- -/--</p>	1-5,7, 11,12

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search  4 May 2012	Date of mailing of the international search report  21/05/2012
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Mandl, Birgit

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2012/050902

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	PRANGISHVILI DAVID ET AL: "Exceptional virion release mechanism: one more surprise from archaeal viruses", CURRENT OPINION IN MICROBIOLOGY, vol. 14, no. 3, Sp. Iss. SI, June 2011 (2011-06), pages 315-320, XP002675302, ISSN: 1369-5274 the whole document	1-5,7, 11,12
X,P	QUAX TESSA E F ET AL: "Simple and elegant design of a virion egress structure in Archaea.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 108, no. 8, 22 February 2011 (2011-02-22), pages 3354-3359, XP002639049, ISSN: 1091-6490 the whole document	1-7, 10-12
A	STEINMETZ N. F. ET AL.: "Site-specific and spatially controlled addressability of a new viral nanobuilding block: Sulfolobus islandicus rod-shaped virus 2", ADVANCED FUNCTIONAL MATERIALS, vol. 18, no. 21, 2008, pages 3478-3486, XP002639050, the whole document	1-15
A	BIZE ARIANE ET AL: "A unique virus release mechanism in the Archaea.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 106, no. 27, 7 July 2009 (2009-07-07), pages 11306-11311, XP002639051, ISSN: 1091-6490 cited in the application the whole document	1-15
A	BASTA TAMARA ET AL: "Nanobiotechnological potential of viruses of hyperthermophilic Archaea" In: 1 January 2008 (2008-01-01), THERMOPHILES, CRC PRESS, BOCA RATON, FLA, XP009148950, pages 225-235, page 228, last paragraph - page 229, last paragraph	1-15
	----- -/--	

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2012/050902

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EVANS DAVID J: "Exploitation of plant and archaeal viruses in bionanotechnology", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 37, no. 4, 1 August 2009 (2009-08-01) , pages 665-670, XP009148923, ISSN: 0300-5127 page 669  -----	1-15